- call +1-201-465-4211
- email sales@mrinsights.biz
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
Scope of the Report:
This report focuses on the Neuromyelitis Optica Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
In the last several years, global market of Neuromyelitis Optica Drug developed with the production growth rate about 4%. In 2015 global capacity of Neuromyelitis Optica Drug is more than 9100 K units.
North America is the largest supplier of Neuromyelitis Optica Drug, with a production market share of 59.3% and a consumption market share of 18.7%.
Europe is the second largest supplier of Neuromyelitis Optica Drug, following North America with the production market share of 25% and the consumption market share of 27%. Asia (Ex China) is another important market of Neuromyelitis Optica Drug, enjoying 31.8% sales market share.
The worldwide market for Neuromyelitis Optica Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Pfizer
FRESENIUS
TEVA
SANDOZ
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Glucocorticoids
Immunoglobulin
Market Segment by Applications, can be divided into
Acute attack
Remission prophylactic treatment
There are 15 Chapters to deeply display the global Neuromyelitis Optica Drug market.
Chapter 1, to describe Neuromyelitis Optica Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Neuromyelitis Optica Drug, with sales, revenue, and price of Neuromyelitis Optica Drug, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Neuromyelitis Optica Drug, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Neuromyelitis Optica Drug market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Neuromyelitis Optica Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Neuromyelitis Optica Drug Introduction
1.2 Market Analysis by Type
1.2.1 Glucocorticoids
1.2.2 Immunoglobulin
1.3 Market Analysis by Applications
1.3.1 Acute attack
1.3.2 Remission prophylactic treatment
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 Neuromyelitis Optica Drug Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 FRESENIUS
2.2.1 Business Overview
2.2.2 Neuromyelitis Optica Drug Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 FRESENIUS Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 TEVA
2.3.1 Business Overview
2.3.2 Neuromyelitis Optica Drug Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 TEVA Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 SANDOZ
2.4.1 Business Overview
2.4.2 Neuromyelitis Optica Drug Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 SANDOZ Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Intas
2.5.1 Business Overview
2.5.2 Neuromyelitis Optica Drug Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Intas Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Gyjtrs
2.6.1 Business Overview
2.6.2 Neuromyelitis Optica Drug Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Gyjtrs Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 NANG KUANG
2.7.1 Business Overview
2.7.2 Neuromyelitis Optica Drug Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 NANG KUANG Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Tianjin Kingyork
2.8.1 Business Overview
2.8.2 Neuromyelitis Optica Drug Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Baxter
2.9.1 Business Overview
2.9.2 Neuromyelitis Optica Drug Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Baxter Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 CSL
2.10.1 Business Overview
2.10.2 Neuromyelitis Optica Drug Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 CSL Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Grifols
2.11.1 Business Overview
2.11.2 Neuromyelitis Optica Drug Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Grifols Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Octapharma
2.12.1 Business Overview
2.12.2 Neuromyelitis Optica Drug Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Octapharma Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 CBOP
2.13.1 Business Overview
2.13.2 Neuromyelitis Optica Drug Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 CBOP Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Neuromyelitis Optica Drug Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Neuromyelitis Optica Drug Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Neuromyelitis Optica Drug Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Neuromyelitis Optica Drug Manufacturer Market Share in 2017
3.3.2 Top 6 Neuromyelitis Optica Drug Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Neuromyelitis Optica Drug Market Analysis by Regions
4.1 Global Neuromyelitis Optica Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Neuromyelitis Optica Drug Sales and Market Share by Regions (2013-2018)
4.1.2 Global Neuromyelitis Optica Drug Revenue and Market Share by Regions (2013-2018)
4.2 North America Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
4.3 Europe Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
4.5 South America Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
5 North America Neuromyelitis Optica Drug by Countries
5.1 North America Neuromyelitis Optica Drug Sales, Revenue and Market Share by Countries
5.1.1 North America Neuromyelitis Optica Drug Sales and Market Share by Countries (2013-2018)
5.1.2 North America Neuromyelitis Optica Drug Revenue and Market Share by Countries (2013-2018)
5.2 United States Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
5.3 Canada Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
5.4 Mexico Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
6 Europe Neuromyelitis Optica Drug by Countries
6.1 Europe Neuromyelitis Optica Drug Sales, Revenue and Market Share by Countries
6.1.1 Europe Neuromyelitis Optica Drug Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Neuromyelitis Optica Drug Revenue and Market Share by Countries (2013-2018)
6.2 Germany Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
6.3 UK Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
6.4 France Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
6.5 Russia Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
6.6 Italy Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
7 Asia-Pacific Neuromyelitis Optica Drug by Countries
7.1 Asia-Pacific Neuromyelitis Optica Drug Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Neuromyelitis Optica Drug Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Neuromyelitis Optica Drug Revenue and Market Share by Countries (2013-2018)
7.2 China Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
7.3 Japan Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
7.4 Korea Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
7.5 India Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
8 South America Neuromyelitis Optica Drug by Countries
8.1 South America Neuromyelitis Optica Drug Sales, Revenue and Market Share by Countries
8.1.1 South America Neuromyelitis Optica Drug Sales and Market Share by Countries (2013-2018)
8.1.2 South America Neuromyelitis Optica Drug Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
8.3 Argentina Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
8.4 Colombia Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
9 Middle East and Africa Neuromyelitis Optica Drug by Countries
9.1 Middle East and Africa Neuromyelitis Optica Drug Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Neuromyelitis Optica Drug Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Neuromyelitis Optica Drug Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
9.3 UAE Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
9.4 Egypt Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
9.5 Nigeria Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
9.6 South Africa Neuromyelitis Optica Drug Sales and Growth Rate (2013-2018)
10 Global Neuromyelitis Optica Drug Market Segment by Type
10.1 Global Neuromyelitis Optica Drug Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Neuromyelitis Optica Drug Sales and Market Share by Type (2013-2018)
10.1.2 Global Neuromyelitis Optica Drug Revenue and Market Share by Type (2013-2018)
10.2 Glucocorticoids Sales Growth and Price
10.2.1 Global Glucocorticoids Sales Growth (2013-2018)
10.2.2 Global Glucocorticoids Price (2013-2018)
10.3 Immunoglobulin Sales Growth and Price
10.3.1 Global Immunoglobulin Sales Growth (2013-2018)
10.3.2 Global Immunoglobulin Price (2013-2018)
11 Global Neuromyelitis Optica Drug Market Segment by Application
11.1 Global Neuromyelitis Optica Drug Sales Market Share by Application (2013-2018)
11.2 Acute attack Sales Growth (2013-2018)
11.3 Remission prophylactic treatment Sales Growth (2013-2018)
12 Neuromyelitis Optica Drug Market Forecast (2018-2023)
12.1 Global Neuromyelitis Optica Drug Sales, Revenue and Growth Rate (2018-2023)
12.2 Neuromyelitis Optica Drug Market Forecast by Regions (2018-2023)
12.2.1 North America Neuromyelitis Optica Drug Market Forecast (2018-2023)
12.2.2 Europe Neuromyelitis Optica Drug Market Forecast (2018-2023)
12.2.3 Asia-Pacific Neuromyelitis Optica Drug Market Forecast (2018-2023)
12.2.4 South America Neuromyelitis Optica Drug Market Forecast (2018-2023)
12.2.5 Middle East and Africa Neuromyelitis Optica Drug Market Forecast (2018-2023)
12.3 Neuromyelitis Optica Drug Market Forecast by Type (2018-2023)
12.3.1 Global Neuromyelitis Optica Drug Sales Forecast by Type (2018-2023)
12.3.2 Global Neuromyelitis Optica Drug Market Share Forecast by Type (2018-2023)
12.4 Neuromyelitis Optica Drug Market Forecast by Application (2018-2023)
12.4.1 Global Neuromyelitis Optica Drug Sales Forecast by Application (2018-2023)
12.4.2 Global Neuromyelitis Optica Drug Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Neuromyelitis Optica Drug Picture
Table Product Specifications of Neuromyelitis Optica Drug
Figure Global Sales Market Share of Neuromyelitis Optica Drug by Types in
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
